Current state of diagnosis and management of critical limb ischemia

Current Cardiology Reports

Volumn 14, Issue 2, 2012, Pages 160-170

  Clair, Dan ^a   Shah, Samir ^a   Weber, John ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Amputation; Aortoiliac disease; Atherosclerosis; BASIL; Claudication; CLI; Critical limb ischemia; Endovascular; Gangrene; Infrainguinal disease; Limb salvage; PAD; Peripheral arterial disease; Peripheral bypass; Rest pain; TASC; Tissue loss

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EDIFOLIGIDE; GADOLINIUM; IODINATED CONTRAST MEDIUM; PLACEBO; SIMVASTATIN;

ANKLE BRACHIAL INDEX; AOROBIFEMORAL BYPASS; AORTA RECONSTRUCTION; AORTOILIAC DISEASE; ARTERY BYPASS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLAUDICATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; CRITICAL LIMB ISCHEMIA; DIABETES MELLITUS; DIGITAL SUBTRACTION ANGIOGRAPHY; DRUG ELUTING STENT; DYSLIPIDEMIA; EXERCISE; HUMAN; HYPERTENSION; INFRAINGUINAL BYPASS; INFRAINGUINAL DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIMB SALVAGE; MAGNETIC RESONANCE ANGIOGRAPHY; NEPHROGENIC SYSTEMIC FIBROSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL EXAMINATION; SMOKING CESSATION; VASCULAR PATENCY; WEIGHT REDUCTION; WOUND INFECTION;

AMPUTATION; ANGIOGRAPHY; CHRONIC PAIN; COMORBIDITY; CRITICAL CARE; CRITICAL ILLNESS; FEMALE; HUMANS; ISCHEMIA; ISCHEMIC POSTCONDITIONING; LIMB SALVAGE; LOWER EXTREMITY; MALE; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; SMOKING CESSATION; UPPER EXTREMITY; WOUND HEALING;

EID: 84861098553     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0251-4     Document Type: Article

References (54)

1. Ostchega Y, Paulose-Ram R, Dillon CF, et al. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc. 2007;55:583-9. (Pubitemid 46496588)
2. Lepantalo M, Matzke S. Outcome of unreconstructed chronic critical leg ischaemia. Eur J Vasc Endovasc Surg. 1996;11:153-7. (Pubitemid 26120467)
3. Wolfe JH, Wyatt MG. Critical and subcritical ischaemia. Eur J Vasc Endovasc Surg. 1997;13:578-82. (Pubitemid 27332193)
4. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31:S1-S296.
5. Gahtan V. The noninvasive vascular laboratory. Surg Clin North Am. 1998;78:507-18. (Pubitemid 28394853)
6. Bettmann MA, Heeren T, Greenfield A, Goudey C. Adverse events with radiographic contrast agents: results of the SCVIR Contrast Agent Registry. Radiology. 1997;203:611-20. (Pubitemid 27227402)
7. Waugh JR, Sacharias N. Arteriographic complications in the DSA era. Radiology. 1992;182:243-6.
8. Lundin P, Svensson A, Henriksen E, et al. Imaging of aortoiliac arterial disease. Duplex ultrasound and MR angiography versus digital subtraction angiography. Acta Radiol. 2000;41:125-32.
9. Kreitner KF, Kalden P, Neufang A, et al. Diabetes and peripheral arterial occlusive disease: prospective comparison of contrastenhanced three-dimensionalMR angiography with conventional digital subtraction angiography. AJR Am J Roentgenol. 2000;174:171-9. (Pubitemid 30030230)
10. Heijenbrok-Kal MH, Kock MC, Hunink MG. Lower extremity arterial disease: multidetector CT angiography meta-analysis. Radiology. 2007;245:433-9. (Pubitemid 47612524)
11. Gandhi S, Weinberg I, Margey R, and Jaff MR. Comprehensive medical management of peripheral arterial disease. Prog Cardiovasc Dis 2011, 54:2-13.
12. Abraira C, Duckworth WC, Moritz T. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab. 2009;11:150-6.
13. Standards of medical care in diabetes - 2010. Diabetes Care 2010, 33 Suppl 1:S11-61.
14. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007, 45:645-654; discussion 653-644.
15. Mohler 3rd ER, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108:1481-6. (Pubitemid 37176455)
16. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006, 113:e463-654.
17. Willigendael EM, Teijink JA, Bartelink ML, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg. 2004;40:1158-65. (Pubitemid 40037284)
18. Price JF, Mowbray PI, Lee AJ, et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J. 1999;20:344-53. (Pubitemid 29103732)
19. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Bmj. 2000;321:412-9. (Pubitemid 30609443)
20. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53.
21. Fox KM, Henderson JR, Bertrand ME, et al. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J 1998, 19 Suppl J:J52-5. (Pubitemid 28427121)
22. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Bmj 2002, 324:71-86.
23. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996, 348:1329-39.
24. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-17.
25. Belch JJ, Dormandy J, Biasi GM, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010, 52:825-833, 833 e821-822.
26. Zukauskas G, Ulevicius H, Janusauskas E. An optimal inflow procedure for multi-segmental occlusive arterial disease: iliofemoral versus aorto-bifemoral bypass. Cardiovasc Surg. 1998; 6:250-5. (Pubitemid 28319760)
27. Carsten 3rd CG, Kalbaugh CA, Langan 3rd EM, et al. Contemporary outcomes of iliofemoral bypass grafting for unilateral aortoiliac occlusive disease: a 10-year experience. Am Surg. 2008;74:555-9. discussion 559-560. (Pubitemid 351768774)
28. Chiu KW, Davies RS, Nightingale PG, et al. Review of direct anatomical open surgical management of atherosclerotic aortoiliac occlusive disease. Eur J Vasc Endovasc Surg. 2010;39:460-71.
29. Mingoli A, Sapienza P, Feldhaus RJ, et al. Comparison of femorofemoral and aortofemoral bypass for aortoiliac occlusive disease. J Cardiovasc Surg (Torino). 2001;42:381-7. (Pubitemid 32700903)
30. Thuijls G, van Laake LW, Lemson MS, Kitslaar PJ. Usefulness and applicability of femorofemoral crossover bypass grafting. Ann Vasc Surg. 2008;22:663-7.
31. Kim YW, Lee JH, Kim HG, Huh S. Factors affecting the long-term patency of crossover femorofemoral bypass graft. Eur J Vasc Endovasc Surg. 2005;30:376-80. (Pubitemid 41258496)
32. Mii S, Eguchi D, Takenaka T, et al. Role of femorofemoral crossover bypass grafting for unilateral iliac atherosclerotic disease: a comparative evaluation with anatomic bypass. Surg Today. 2005;35:453-8. (Pubitemid 40873807)
33. Aburahma AF, Robinson PA, Cook CC, Hopkins ES. Selecting patients for combined femorofemoral bypass grafting and iliac balloon angioplasty and stenting for bilateral iliac disease. J Vasc Surg. 2001;33:S93-99. (Pubitemid 32172836)
34. Ricco JB, Probst H. Long-term results of a multicenter randomized study on direct versus crossover bypass for unilateral iliac artery occlusive disease. J Vasc Surg. 2008;47:45-53. discussion 53-44.
35. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007, 45 Suppl S:S5-67.
36. Zander T, Blasco O, Rabellino M, et al. Bifurcated endograft in aortoiliac type C and D lesions: long-term results. J Vasc Interv Radiol. 2011;22:1124-30.
37. Nishibe T, Kondo Y, Dardik A, et al. Hybrid surgical and endovascular therapy in multifocal peripheral TASC D lesions: up to three-year follow-up. J Cardiovasc Surg (Torino). 2009;50:493-9.
38. Leville CD, Kashyap VS, Clair DG, et al. Endovascular management of iliac artery occlusions: extending treatment to TransAtlantic Inter-Society Consensus class C and D patients. J Vasc Surg. 2006;43:32-9. (Pubitemid 43083505)
39. Schanzer A, Hevelone N, Owens CD, et al. Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. J Vasc Surg. 2007;46:1180-90. discussion 1190. (Pubitemid 350267083)
40. ConteMS. Technical factors in lower-extremity vein bypass surgery: how can we improve outcomes? Semin Vasc Surg. 2009;22:227-33.
41. Clark TW, Groffsky JL, Soulen MC. Predictors of long-term patency after femoropopliteal angioplasty: results from the STAR registry. J Vasc Interv Radiol. 2001;12:923-33. (Pubitemid 32756861)
42. Muradin GS, Bosch JL, Stijnen T, Hunink MG. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology. 2001;221:137-45. (Pubitemid 32880382)
43. Kandarpa K, Becker GJ, Hunink MG, et al. Transcatheter interventions for the treatment of peripheral atherosclerotic lesions: part I. J Vasc Interv Radiol. 2001;12:683-95. (Pubitemid 32521156)
44. Met R, Van Lienden KP, Koelemay MJ, et al. Subintimal angioplasty for peripheral arterial occlusive disease: a systematic review. Cardiovasc Intervent Radiol. 2008;31:687-97.
45. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007; 115:2745-9. (Pubitemid 46842791)
46. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-76.
47. Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701-10. (Pubitemid 44907633)
48. Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16:331-8. (Pubitemid 40354849)
49. Lammer J, Bosiers M, Zeller T, et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg 2011, 54:394-401.
50. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689-99. (Pubitemid 351240748)
51. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358-65.
52. Romiti M, Albers M, Brochado-Neto FC, et al. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47:975-81.
53. Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925-34. (Pubitemid 41713982)
54. Conte MS. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia. J Vasc Surg 2010, 51:69S-75S.